Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of TQB2916 plus gemcitabine and nab-paclitaxel in first-line metastatic pancreatic ductal adenocarcinoma
ChiCTR2400095041Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TQB2916, gemcitabine and paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Peking Union Medical College Hospital. Primary endpoint: 6-month progression-free survival rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
TQB2916gemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2400095041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400095041.